EMBLEM S-ICD Electrode (Lead)
BOSTON SCIENTIFIC CORPORATION · Decision date Feb 20, 2026
What did the FDA approve?
FDA records P110042/S203 as a supplement to PMA P110042, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Feb 20, 2026.
FDA approval order statement
multiple design changes to the EMBLEM S-ICD Electrode including improvement in fatigue endurance, and changes in insulation material and supplier, and updates to various subcomponents.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Feb 20, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P110042/S203
- Regulatory pathway
- PMA supplement
- Applicant
- BOSTON SCIENTIFIC CORPORATION
- Product code
- LWS
- Decision code
- APPR
- Decision date
- Feb 20, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implantable cardioverter defibrillator (non-CRT).
- Applicant
- Boston Scientific Corporation
- Product code
- LWS
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P110042. Subsequent supplements may change the device or its indications.
FDA decision timeline
P110042 · Original PMA
SUBCUTANEOUS IMPLANTABLE DEFIBRILLATOR (S-ICD) SYSTEM
P110042/S203 received
Application receipt date recorded by FDA.
P110042/S205 · Related supplement
SUBCUTANEOUS IMPLANTABLE DEFIBRILLATOR (S-ICD) SYSTEM
P110042/S206 · Related supplement
A209 SICD Gen 2,A219 SICD MRI
P110042/S204 · Related supplement
Subcutaneous Implantable Cardioverter Defibrillator (S-ICD): EMBLEM S-ICD Model A209 and EMBLEM MRI S-ICD Model A219
P110042/S208 · Related supplement
EMBLEM S-ICD/ model 3501
P110042/S207 · Related supplement
EMBLEM S-ICD subcutaneous electrode/lead
P110042/S203 · FDA decision
Normal 180 Day Track
P110042/S209 · Related supplement
EMBLEM S-ICD subcutaneous electrode/lead
P110042/S212 · Related supplement
EMBLEM, EMBLEM MRI
P110042/S213 · Related supplement
S-ICD Electrode Model: 3501
P110042/S211 · Related supplement
EMBLEM S-ICD
P110042/S214 · Related supplement
Emblem S-ICD (A209); Emblem MRI S-ICD (A219)
P110042/S210 · Related supplement
EMBLEM S-ICD Electrode (Lead) Model 3501
P110042/S215 · Related supplement
S-ICD EMBLEM GEN 2 (A209); S-ICD EMBLEM MRI (A219)
P110042/S216 · Related supplement
EMBLEM Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) high voltage (HV) Capacitor
Timeline entries are records held by MedtechLedger for P110042. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P110042
Explore the linked device profile
Other records with product code LWS
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Nov 4, 2026 | FDA | |
Cobalt MRI ICD, Cobalt XT MRI ICD, Crome MRI ICDP980016/S967 | Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 29, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corporation
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 4100 Hamline Ave. N, St Paul, MN, 55112
Sources and methodology
- Original FDA record: P110042/S203
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






